NOVABIO Research Profile

What Is Long R3 Insulin-Like Growth Factor-1 (IGF-1 LR3)?

IGF-1 LR3 is a long R3 insulin-like growth factor-1 analogue used in growth-factor signaling research contexts. This page identifies the material as Long R3 Insulin-Like Growth Factor-1 (IGF-1 LR3), with amino acid count 83; synonyms Long R3 Insulin-like Growth Factor-1. The IGF-1 LR3 identifiers distinguish this catalogue entry from similarly named compounds, fragments, modified analogues, and multi-component formulations. Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Exact-product regulatory reviewLast verified 2026-10-06
Catalogue identityLong R3 Insulin-Like Growth Factor-1 (IGF-1 LR3)
Available specifications0.1mg, 1mg
Evidence snapshot0 trials · 79 publications
Last verified2026-10-06

What Is Long R3 Insulin-Like Growth Factor-1 (IGF-1 LR3)?

IGF-1 LR3 is a long R3 insulin-like growth factor-1 analogue used in growth-factor signaling research contexts. This page identifies the material as Long R3 Insulin-Like Growth Factor-1 (IGF-1 LR3), with amino acid count 83; synonyms Long R3 Insulin-like Growth Factor-1. The IGF-1 LR3 identifiers distinguish this catalogue entry from similarly named compounds, fragments, modified analogues, and multi-component formulations.

Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Evidence at a Glance

0ClinicalTrials.gov query records
79PubMed query records
6Selected publications shown

Sources: ClinicalTrials.gov query · PubMed query · Retrieved 2026-10-06

Mechanism & Pharmacology

The research record for IGF-1 LR3 is organized around growth-factor receptor research, ligand profiling, protein-signaling literature, and analytical peptide characterization. For IGF-1 LR3, those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome.

Mechanistic or pathway language defines a research scope. It does not establish that a catalogue product produces a clinical effect.

Clinical Development

Selected exact-query registry records are shown below. Desktop displays up to six; mobile displays up to three.

NCT ID / StudyPhaseStatusContextLast registry update
No exact-match registry records were returned by the displayed query at the retrieval time.

Source: ClinicalTrials.gov search · Retrieved 2026-10-06

Selected Literature6 important records shown

Selected Literature

Selected PubMed record

Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice.

Journal of Alzheimer's disease : JAD · 2025 Jan

PMID 39610283
Selected PubMed record

Roles of insulin-like growth factor-I (IGF-I) and IGF-I binding protein-2 (IGFBP2) and -5 (IGFBP5) in developing chick limbs.

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2001 Dec

PMID 11914022
Selected PubMed record

Action of long(R3)-insulin-like growth factor-1 on protein metabolism in beef heifers.

Domestic animal endocrinology · 1999 May

PMID 10370861
Selected PubMed record

Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris.

Applied microbiology and biotechnology · 2023 Jul

PMID 37261455
Selected PubMed record

IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep.

American journal of physiology. Endocrinology and metabolism · 2025 Jan 1

PMID 39679943
Selected PubMed record

Long [R3] insulin-like growth factor-I reduces growth, plasma growth hormone, IGF binding protein-3 and endogenous IGF-I concentrations in pigs.

The Journal of endocrinology · 1997 Dec

PMID 9488001

Source: PubMed search results · Retrieved 2026-10-06

Identity & ChemistryProduct-form fields

Identity & Chemistry

Compound / Blend
Long R3 Insulin-Like Growth Factor-1 (IGF-1 LR3)
Available Specifications
0.1mg, 1mg
Pack Format
10 Vials
Amino Acid Count
83
Sequence
83-residue IGF-I analogue with a Glu3→Arg substitution and a 13-residue N-terminal extension.
Synonyms
Long R3 Insulin-like Growth Factor-1
Physical Form
Lyophilized powder

Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Source: NOVABIO product identity record · No single PubChem record is asserted for this catalogue entry.

Research Tools for Long R3 Insulin-Like Growth Factor-1 (IGF-1 LR3)

Review the selected registry records and open the module-level ClinicalTrials.gov query for the current result set.

Open Clinical Development

Use the complete NOVABIO documentation library to review currently available batch records.

Open Lab Results & COA
Storage & Laboratory HandlingDocumentation-led controls

Storage & Laboratory Handling

Confirm the exact material form, lot, supplied state and storage statement from the product label and corresponding batch documentation. Do not infer handling conditions from a different compound, strength or external clinical publication.

Regulatory Status

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Source: FDA Drugs@FDA · Checked 2026-10-06

Authoritative Data Summary

Long R3 Insulin-Like Growth Factor-1 (IGF-1 LR3) Research Summary

Identity

Long R3 Insulin-Like Growth Factor-1 (IGF-1 LR3); specifications: 0.1mg, 1mg. Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Mechanism

The research record for IGF-1 LR3 is organized around growth-factor receptor research, ligand profiling, protein-signaling literature, and analytical peptide characterization. For IGF-1 LR3, those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome.

Evidence

0 registry records and 79 PubMed records were returned by the displayed query on 2026-10-06; counts are not quality ratings.

Regulatory context

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Long R3 Insulin-Like Growth Factor-1 (IGF-1 LR3) is represented here by the catalogue identity Long R3 Insulin-Like Growth Factor-1 (IGF-1 LR3). Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation. The product record lists 0.1mg, 1mg as the currently available specifications. The research context is organized around this product-specific scope: The research record for IGF-1 LR3 is organized around growth-factor receptor research, ligand profiling, protein-signaling literature, and analytical peptide characterization. For IGF-1 LR3, those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome. The synchronized searches returned 0 ClinicalTrials.gov records and 79 PubMed records for the displayed query. A registry count includes records with different designs, statuses and populations, while a publication count can include reviews, preclinical work and unrelated uses of a shared abbreviation; neither count is a quality score. For regulatory interpretation, FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval. Clinical findings apply only to the studied drug product, formulation, population and protocol. NOVABIO product specifications and batch documentation are separate catalogue records and do not inherit clinical outcomes from external studies. This profile supports identity checking, source tracing and laboratory record review; it does not certify a batch, recommend treatment, provide dosing instructions or replace current official labeling and professional judgment.

Sources: PubMed · ClinicalTrials.gov · FDA · NOVABIO product record

FAQ4 evidence-bounded answers

Long R3 Insulin-Like Growth Factor-1 (IGF-1 LR3) FAQ

What is Long R3 Insulin-Like Growth Factor-1 (IGF-1 LR3)?

IGF-1 LR3 is a long R3 insulin-like growth factor-1 analogue used in growth-factor signaling research contexts. This page identifies the material as Long R3 Insulin-Like Growth Factor-1 (IGF-1 LR3), with amino acid count 83; synonyms Long R3 Insulin-like Growth Factor-1. The IGF-1 LR3 identifiers distinguish this catalogue entry from similarly named compounds, fragments, modified analogues, and multi-component formulations.

What research records are indexed for Long R3 Insulin-Like Growth Factor-1 (IGF-1 LR3)?

The synchronized query returned 0 ClinicalTrials.gov records and 79 PubMed records on 2026-10-06; review the linked searches because counts and record status can change.

Is Long R3 Insulin-Like Growth Factor-1 (IGF-1 LR3) FDA approved?

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Does this page provide dosing guidance?

No. This research profile provides identity, evidence, chemistry, regulatory and documentation context without dosing or treatment instructions.

Sources, Methodology & Last Verified

Official sources
ClinicalTrials.gov, NCBI PubMed, FDA, available PubChem records, and NOVABIO product and COA records.
Query retrieved
2026-10-06T12:08:49Z
Inclusion
Exact identity terms and traceable registry, publication, chemistry, regulatory or catalogue fields.
Limitations
Search counts can include mixed evidence types and shared-name records; individual records require direct review.
Prepared by
NOVABIO Research
Reviewed date
2026-10-06
Editorial methodology
How NOVABIO builds Research Profiles
Corrections contact
Contact NOVABIO with the page URL and source record.